

Erratum: Phase 1 First-in-Human Dose Escalation and Dose Expansion Study of KLS-1 (64Zinc Aspartate) in Patients With Cancer and Neurodegenerative Diseases

Article published 10/04/2022

Article corrected 10/14/2022

Jesus A. Perez¹, Javier J. Lopez², Claudia C. Torres Badillo³, Jaya Gill⁴, Santosh Kesari⁴, Peter Novak⁵, Max Temnikov⁵, Roman Byshovets⁶, Oleg Bychkov⁶

1. Medicine, Pan American Cancer Treatment Center, Tijuana, MEX 2. Neurology, Pan American Cancer Treatment Center, Tijuana, MEX 3. General Practice, Pan American Cancer Treatment Center, Tijuana, MEX 4. Department of Translational Neurosciences, Pacific Neuroscience Institute and Saint John's Cancer Institute at Providence Saint John's Health Center, Santa Monica, USA 5. Physical Chemistry, Vector Vitale, North Miami Beach, USA 6. Research, Vector Vitale, North Miami Beach, USA

Corresponding author: Jesus A. Perez, jesus.perez.md@gmail.com

Corresponding author: Jesus A. Perez

1. Medicine, Pan American Cancer Treatment Center, Tijuana, MEX 2. Neurology, Pan American Cancer Treatment Center, Tijuana, MEX 3. General Practice, Pan American Cancer Treatment Center, Tijuana, MEX 4. Department of Translational Neurosciences, Pacific Neuroscience Institute and Saint John's Cancer Institute at Providence Saint John's Health Center, Santa Monica, USA 5. Physical Chemistry, Vector Vitale, North Miami Beach, USA 6. Research, Vector Vitale, North Miami Beach, USA

How to cite this erratum

Perez J A, Lopez J J, Torres Badillo C C, et al. (October 14, 2022) Correction: Phase 1 First-in-Human Dose Escalation and Dose Expansion Study of KLS-1 (64Zinc Aspartate) in Patients With Cancer and Neurodegenerative Diseases. *Cureus* 14(10): c78. doi:10.7759/cureus.c78

Correction Notice

Authors Jaya Gill and Santosh Kesari have been added to the published article after they were mistakenly omitted from the original submission by the submitting author. The authors deeply regret this error.